Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
SurvivorNet on MSN
Cancer patients are living longer — a closer look at the treatments driving this progress
New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...
The world's first CDK2/4/6 inhibitor, developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical, was officially approved for market launch on Thursday. CDK2/4/6 ...
SAN FRANCISCO and SUZHOU, China, Dec. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
TABOSUN ® (ipilimumab N01 injection) has been approved in combination with TYVYT ® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite ...
Through Innovent's efficient and high-quality clinical development, ipilimumab N01 has become China's first domestically developed innovative CTLA-4 inhibitor approved by the NMPA, offering a new ...
Through Innovent's efficient and high-quality clinical development, ipilimumab N01 has become China's first domestically developed innovative CTLA-4 inhibitor approved by the NMPA, offering a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback